Pre-designed mRNA vaccines matched to patients based on their tumour's antigen profile.
Unlike personalised neoantigen vaccines that are manufactured individually for each patient, off-the-shelf mRNA cancer vaccines using mRNA immunotherapy target shared tumour-associated antigens that are commonly expressed across patients with the same cancer type. Tumour profiling identifies which antigens are present, and a matching pre-manufactured cancer vaccine is selected for rapid deployment.
A streamlined three-step process from tumour profiling to mRNA immunotherapy vaccine delivery.
Tumour and matched healthy tissue samples are analysed using RNA sequencing and protein profiling to identify which known tumour-associated antigens are expressed in the patient's cancer.
Based on the antigen profile, a matching pre-manufactured mRNA vaccine is selected from a library of validated constructs targeting commonly expressed tumour-associated antigens.
The mRNA-LNP vaccine is administered to the patient. Antigen presenting cells take up the LNP, present tumour antigens, and stimulate T cell expansion to attack the tumour.
Both personalised and off-the-shelf approaches harness mRNA-LNP technology with mRNA immunotherapy to train the immune system against cancer, but differ in their targeting strategy. Personalised mRNA cancer vaccines target unique mutations (neoantigens) in an individual's tumour, while off-the-shelf cancer vaccines target shared antigens that are commonly overexpressed across many patients with the same cancer type.
The off-the-shelf mRNA cancer vaccine approach trades the precision of patient-specific neoantigens for speed and scalability — vaccines are pre-manufactured and ready to deploy immediately after tumour profiling, without the weeks required for custom mRNA design and manufacturing.
Learn more about our personalised mRNA vaccine pipeline and targeted mRNA delivery technology.